TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06771219: SLV-154 Treatment of Advanced Cancers

Sponsor: Solve Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06771219 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06771219 Rescue Dossier →